Article Details

Alumis, a biotech focused on immune-mediated diseases, files for a $100 million IPO

Retrieved on: 2024-06-08 10:01:43

Tags for this article:

Click the tags to see associated articles and topics

Alumis, a biotech focused on immune-mediated diseases, files for a $100 million IPO. View article details on hiswai:

Excerpt

Morgan Stanley, Leerink Partners, Cantor Fitzgerald, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were ...

Article found on: www.renaissancecapital.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up